



11-530-C100

Monoclonal Antibody to CD79a Purified Antibody (0.1 mg)

Clone:	HM57
Isotype:	Mouse IgG1
Specificity:	The antibody HM57 interacts with CD79a (Ig alpha), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms. HLDA V; WS Code BC cB018 HLDA VI; WS Code BP 193 HLDA VI; WS Code BP 89 HLDA VI; WS Code B B103 HLDA VI; WS Code B CD79.4
Immunogen:	Synthetic peptide corresponding to amino acids 202-216 of human CD79a
Species Reactivity:	Human, Porcine, Mouse, Rat, Bovine, Equine (Horse), Guinea pig, Opossum, Rabbit, Chicken, Other not determined
Application:	Flow Cytometry Recommended dilution: 5 µg/ml Immunohistochemistry (paraffin sections) Recommended dilution: 10 µg/ml Immunohistochemistry (frozen sections)
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified from hybridoma culture supernatant by protein-A affinity chromatography.
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20°C. Avoid freeze/thaw cycles.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD79a (Ig alpha, MB1) forms disulfide-linked heterodimer with CD79b (Ig beta). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *Bannish G, Fuentes-Pananá EM, Cambier JC, Pear WS, Monroe J.G.: Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. *J Exp Med.* 2001 Dec 3;194(11):1583-96.
- *Pike KA, Iacampo S, Friedmann JE, Ratcliffe M.J.: The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. *J Immunol.* 2004 Feb 15;172(4):2210-8.
- *Fuentes-Pananá EM, Bannish G, Shah N, Monroe J.G.: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. *J Immunol.* 2004 Jul 15;173(2):1000-11.
- *Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe J.G.: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. *J Immunol.* 2005 Feb 1;174(3):1245-52.
- *Fuentes-Pananá EM, Bannish G, Karnell FG, Trembl JF, Monroe J.G.: Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. *J Immunol.* 2006 Dec 1;177(11):7913-22.
- *van Noesel CJ, van Lier RA, Cordell JL, Tse AG, van Schijndel GM, de Vries EF, Mason DY, Borst J.: The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene. *J Immunol.* 1991 Jun 1;146(11):3881-8.
- *Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al.: The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. *J Immunol.* 1991 Dec 1;147(11):2474-82.
- *Mason DY, van Noesel CJ, Cordell JL, Comans-Bitter WM, Micklem K, Tse AG, van Lier RA, van Dongen J.J.: The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. *Eur J Immunol.* 1992 Oct;22(10):2753-6.
- *Jones M, Cordell JL, Beyers AD, Tse AG, Mason D.Y.: Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. *J Immunol.* 1993 Jun 15;150(12):5429-35.
- *Mason DY, Cordell JL, Brown MH, Borst J, Jones M, Pulford K, Jaffe E, Ralfkiaer E, Dallenbach F, Stein H, et al: CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. *Blood.* 1995 Aug 15;86(4):1453-9.
- *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
- *Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
- *Faldyna M, Samankova P, Leva L, Cerny J, Oujezdska J, Rehakova Z, Sinkora J: Cross-reactive anti-human monoclonal antibodies as a tool for B-cell identification in dogs and pigs. *Vet Immunol Immunopathol.* 2007 Sep 15;119(1-2):56-62.

For laboratory research only, not for drug, diagnostic or other use.